We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
- Authors
Nowakowski, Grzegorz S.; Yoon, Dok Hyun; Mondello, Patrizia; Joffe, Erel; Peters, Anthea; Fleury, Isabelle; Greil, Richard; Ku, Matthew; Marks, Reinhard; Kim, Kibum; Zinzani, Pier Luigi; Trotman, Judith; Sabatelli, Lorenzo; Waltl, Eva E.; Winderlich, Mark; Sporchia, Andrea; Kurukulasuriya, Nuwan C.; Cordoba, Raul; Hess, Georg; Salles, Gilles
- Abstract
RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are autologous stem cell transplant ineligible. We present outcomes data for three pre-specified treatments not assessed in the primary analysis. Data were retrospectively collected from sites in North America, Europe, and the Asia Pacific region. Patients were aged ≥18 years with histologically confirmed DLBCL and received ≥2 systemic therapies for DLBCL (including ≥1 anti-CD20 therapy). Patients enrolled in the observational and L-MIND cohorts were matched using propensity score-based 1:1 nearest-neighbor matching, balanced for six covariates. Tafasitamab+lenalidomide was compared with polatuzumab vedotin+bendamustine+rituximab (pola-BR), rituximab+lenalidomide (R2), and CD19-chimeric antigen receptor T-cell (CAR-T) therapies. The primary endpoint was overall survival (OS). Secondary endpoints included treatment response and progression-free survival. From 200 sites, 3,454 patients were enrolled in the observational cohort. Strictly matched patient pairs consisted of tafasitamab+lenalidomide versus pola-BR (n = 24 pairs), versus R2 (n = 33 pairs), and versus CAR-T therapies (n = 37 pairs). A significant OS benefit was observed with tafasitamab+lenalidomide versus pola-BR (HR: 0.441; p = 0.034) and R2 (HR: 0.435; p = 0.012). Comparable OS was observed in tafasitamab+lenalidomide and CAR-T cohorts (HR: 0.953, p = 0.892). Tafasitamab+lenalidomide appeared to improve survival outcomes versus pola-BR and R2, and comparable outcomes were observed versus CAR-T. Although based on limited patient numbers, these data may help to contextualize emerging therapies for R/R DLBCL. Clinical trial registration: NCT04697160 (January 6, 2021)
- Subjects
DIFFUSE large B-cell lymphomas; LENALIDOMIDE; RITUXIMAB; ANTIGEN receptors; STEM cell transplantation
- Publication
Annals of Hematology, 2023, Vol 102, Issue 7, p1773
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s00277-023-05196-4